GLP-1関連製品市場規模、成長と動向分析レポート 2026-2033年

世界のGLP-1関連製品市場の規模は、2025年に2,048億米ドルと評価され、2026年から2033年にかけて年平均成長率（CAGR）11.3%で推移し、2026年の2,259億米ドルから2033年には4,790億米ドルに拡大すると予測されています。2025年時点では、北米が37.8%の市場シェアを占め、最大規模となりました。GLP-1製剤の利用者の間では、治療中の食欲低下への対処、適切なタンパク質摂取のサポート、水分補給、消化器系の健康維持、そして除脂肪筋肉量の維持に役立つ製品への需要が高まっています。

市場の主な動向とインサイト

• 製品別：2025年、水分補給・リカバリー製品が収益シェアの26.2%を占めました。
• 流通チャネル別：2025年、オンライン販売チャネルが収益シェアの23.6%を占めました。

地域別のハイライト

• 最大の地域市場：北米（2025年時点で収益シェア37.8%）
• 最も急成長している地域市場：アジア太平洋地域（2026年～2033年の期間で最高のCAGRを記録）
• 国別：2025年時点で米国が最大の市場シェアを占めました。

こうした傾向を受け、メーカー各社はGLP-1受容者の特有のニーズに合わせた専門的な製品群の開発を進めています。具体的には、高タンパクな食品・飲料、水分補給製品、消化器系の健康をサポートする製品、食事代替品、栄養密度の高いサプリメントなどが挙げられます。パーソナライズされた栄養管理、予防医療、そして長期的な体重管理への関心の高まりが、市場の拡大を加速させています。デジタルヘルス・プラットフォーム、栄養指導、AIを活用したウェルネス・プログラムの導入が進むことで、消費者の関与や治療の継続率（アドヒアランス）が向上しています。同時に、継続的な製品イノベーションや、食品・栄養・ウェルネス関連企業によるGLP-1エコシステムへの参入が、GLP-1関連製品市場に新たな成長機会をもたらし続けています。

GLP-1療法に伴う栄養面や生活習慣上の課題に対する認識が高まるにつれ、消費者が日々の健康管理に専門的なサポート製品を取り入れるようになり、市場は成長を続けています。食欲減退や食事量の減少、消化器系の不調、水分補給への懸念、除脂肪体重（筋肉量）減少のリスクといった課題に対し、消費者は治療中の健康維持を助ける製品を求めています。具体的には、高タンパク食品・飲料、水分補給製品、消化器系ケア製品、微量栄養素サプリメントなどが選ばれています。さらに、予防医療、健康的な加齢（ヘルシーエイジング）、長期的な体重管理への関心が高まる中、適切な栄養状態を維持し、治療効果を持続させるための関連製品に対する需要も拡大しています。

製品に関する考察

GLP-1受容者の間で脱水、電解質バランスの乱れ、疲労、食事摂取量の減少、消化器系の副作用といった症状が広く見られることを背景に、2025年における水分補給・リカバリー（回復）製品セグメントの収益シェアは26.2%を占めました。食欲抑制は食事や水分の摂取量減少につながることが多いため、治療中のエネルギーレベル維持や全体的な健康維持を目的として、水分補給製品、電解質サプリメント、リカバリー飲料、栄養価の高い製品を求める消費者が増えています。特定のユーザー層を対象とする代謝サポート製品とは異なり、水分補給製品は、治療の開始から長期的な維持期に至るまで、より幅広い消費者層に訴求するものです。こうした状況を受け、メーカー各社は、GLP-1療法に伴う栄養面での課題に対処するため、電解質、タンパク質、ビタミン、ミネラルを配合した水分補給重視の製品を次々と投入しています。2026年1月、Maeva社は代謝の健康を支援する専用プラットフォームを立ち上げました。同プラットフォームでは、GLP-1受容者向けに特別に配合された水分補給サポート製品に加え、減量治療中の体力維持や回復を支えるためのパーソナライズされた栄養ソリューションが提供されています。

本レポートは、世界、地域、および国レベルでの収益成長を予測するとともに、2021年から2033年にかけての各サブセグメントにおける最新の業界動向と機会を分析しています。本調査において、Grand View Researchは世界のGLP-1関連製品市場を、製品、流通チャネル、および地域に基づいて区分しています。

GLP-1 Companion Products Market Summary

The global GLP-1 companion products market size was valued at USD 204.8 billion in 2025 and is projected to grow from USD 225.9 billion in 2026 to USD 479.0 billion by 2033, at a CAGR of 11.3% from 2026 to 2033. North America held the largest market share of 37.8% in 2025. Consumers using GLP-1 medications are increasingly seeking products that help address reduced appetite, support adequate protein intake, maintain hydration, promote digestive health, and preserve lean muscle mass during treatment.

This trend is encouraging manufacturers to develop specialized product portfolios, including high-protein foods and beverages, hydration solutions, digestive-health products, meal replacements, and nutrient-dense supplements tailored to the unique needs of GLP-1 users. The growing emphasis on personalized nutrition, preventive healthcare, and long-term weight-management support is accelerating market expansion. The increasing integration of digital health platforms, nutrition coaching, and AI-enabled wellness programs is further enhancing consumer engagement and treatment adherence, while ongoing product innovation and the entry of food, nutrition, and wellness companies into the GLP-1 ecosystem continue to create new growth opportunities for the GLP-1 companion product industry.

The market is growing as rising awareness of the nutritional and lifestyle challenges associated with GLP-1 therapy encourages consumers to adopt specialized support products into their daily health routines. Reduced appetite, lower food intake, digestive discomfort, hydration concerns, and the risk of lean muscle loss are prompting consumers to seek protein-enriched foods and beverages, hydration solutions, digestive health products, and micronutrient supplements to support overall well-being during treatment. In addition, the growing emphasis on preventive healthcare, healthy aging, and long-term weight management is accelerating demand for companion products that can help individuals maintain nutritional adequacy and sustain treatment outcomes.

Market Dynamics

Driver: Increasing Commercialization of GLP-1-Focused Food and Beverage Products

The rapid expansion of the GLP-1 user population is encouraging food and beverage manufacturers to develop products tailored to changing consumption patterns associated with appetite suppression and reduced meal frequency. Consumers are increasingly seeking nutrient-dense foods that deliver greater nutritional value in smaller portions, prompting companies to reformulate existing products and launch new offerings specifically for GLP-1 users. This trend is accelerating product innovation and expanding the addressable market for companion nutrition solutions.

In May 2025, Danone expanded its Oikos brand with the launch of Oikos Protein Shakes, citing growing demand among consumers using GLP-1 medications seeking convenient, protein-rich nutrition to support their dietary needs.

Restraint: Gastrointestinal Side Effects Limiting Consumer Adherence

Gastrointestinal side effects remain a significant barrier to long-term adherence to GLP-1 therapy and, consequently, the demand for companion products. Nausea, vomiting, constipation, bloating, and digestive discomfort are among the most frequently reported side effects associated with GLP-1 medications. While companion products are often developed to help manage these challenges, persistent adverse effects may lead some individuals to reduce dosage, discontinue treatment, or avoid initiating therapy altogether. Lower therapy adherence directly reduces the addressable consumer base for companion nutrition and wellness products, limiting opportunities for market expansion.

Multiple clinical reviews and real-world studies continue to identify gastrointestinal adverse events as one of the primary reasons for discontinuation of GLP-1 therapies, highlighting a persistent challenge for long-term treatment adherence.

Consumer Insights

GLP-1 companion products are increasingly being perceived as an essential component of the overall weight-management and wellness journey, rather than as standalone nutritional products. As the use of GLP-1 therapies expands globally, consumers are becoming more conscious of the nutritional and lifestyle adjustments required during treatment, including maintaining adequate protein intake, supporting hydration, managing digestive comfort, and preserving overall nutritional balance. This shift in consumer behavior has contributed to growing demand for companion products across major markets such as the U.S., Canada, Germany, the UK, Australia, and other developed healthcare economies. To address these evolving needs, manufacturers are increasingly introducing specialized product portfolios tailored to GLP-1 users.

Personalization and outcome-oriented nutrition have emerged as key purchasing considerations among GLP-1 users. Rather than seeking general wellness products, consumers increasingly prefer solutions that address specific treatment-related needs and can be incorporated into structured weight-management routines. The growing use of digital health platforms, telehealth services, and nutrition-coaching programs has further strengthened consumer awareness regarding the importance of balanced nutrition throughout treatment. As a result, demand is increasing for convenient, nutrient-dense products such as ready-to-drink protein beverages, meal replacements, functional snacks, electrolyte formulations, probiotics, and micronutrient supplements. Consumers are also demonstrating a preference for products that provide transparent nutritional information, clinically supported ingredients, and clear functional benefits that align with their weight-management objectives.

Product Insights

The hydration & recovery product market segment accounted for a revenue share of 26.2% in 2025, driven by the prevalence of dehydration, electrolyte imbalance, fatigue, reduced food intake, and gastrointestinal side effects among GLP-1 users. As appetite suppression often leads to reduced food and fluid intake, consumers increasingly seek hydration solutions, electrolyte supplements, recovery beverages, and nutrient-dense formulations to help maintain energy levels and support overall wellness during treatment. Unlike specialized metabolic support products that target a specific subset of users, hydration products appeal to a broader consumer base throughout the entire treatment journey, from initiation through long-term maintenance. Consequently, manufacturers are increasingly introducing hydration-focused formulations enriched with electrolytes, protein, vitamins, and minerals to address the nutritional challenges associated with GLP-1 therapy. In January 2026, Maeva launched a dedicated metabolic wellness platform featuring hydration support products specifically formulated for GLP-1 users, alongside personalized nutrition solutions designed to support strength and recovery during weight-loss treatment.

The appetite & metabolic support products market segment is expected to grow at a CAGR of 12.5% from 2026 to 2033, as consumers increasingly seek solutions that complement the physiological effects of GLP-1 therapies and support long-term metabolic health. While GLP-1 medications effectively suppress appetite, many users require additional nutritional support to manage reduced food intake, maintain nutrient adequacy, preserve lean muscle mass, and sustain metabolic function. This has led to growing demand for protein-enriched products, fiber supplements, metabolic wellness formulations, nutrient-dense meal replacements, and specialized dietary solutions designed specifically for individuals undergoing GLP-1 treatment. As consumers become more focused on maintaining results beyond active weight loss, appetite and metabolic support products are gaining traction as an essential component of comprehensive obesity management.

For instance, in May 2025, Oikos expanded beyond yogurt and introduced protein shakes specifically developed for users of GLP-1 medications, addressing increasing demand for protein-rich metabolic support products.

Distribution Channel Insights

The sales of GLP-1 companion products through online channels accounted for a revenue share of 23.6% in 2025, owing to their ability to provide convenient access to specialized nutrition products, hydration solutions, supplements, meal replacements, and wellness programs tailored for GLP-1 users. Consumers undergoing GLP-1 therapy frequently seek personalized products and educational resources that may not be readily available through traditional retail channels, making online platforms a preferred purchasing destination. Additionally, subscription-based purchasing models, direct access to product information, recurring delivery services, telehealth integration, and personalized product recommendations have further strengthened consumer reliance on e-commerce platforms. The channel also enables brands to directly engage with consumers, gather health and behavioral insights, and rapidly introduce new GLP-1-focused offerings in response to evolving market needs.

The sales of GLP-1 companion products through the D2C channel are expected to grow at a CAGR of 13.1% from 2026 to 2033 as brands increasingly seek to establish direct relationships with consumers and deliver personalized support throughout their treatment journey. D2C platforms enable companies to combine product sales with digital coaching, symptom tracking, nutritional guidance, subscription services, and telehealth support, creating comprehensive wellness ecosystems tailored to the specific needs of GLP-1 users. Consumers are increasingly favoring D2C models due to the convenience of home delivery, personalized product recommendations, flexible subscription options, and access to educational content that supports long-term weight management. Moreover, D2C strategies enable companies to collect real-time consumer feedback and rapidly refine product offerings in response to evolving patient needs and treatment experiences.

Regional Insights

The GLP-1 companion products market in North America accounted for a revenue share of 37.8% in 2025, driven by the rapid commercialization of specialized nutrition solutions designed to address the evolving needs of individuals using GLP-1 therapies. Consumers are increasingly seeking products that help maintain adequate protein intake, hydration levels, digestive health, and overall nutritional balance while undergoing weight-management treatment. Another important factor supporting market growth is the increasing integration of companion products into broader health and wellness ecosystems. Companies are expanding beyond standalone nutritional offerings and introducing personalized programs that combine dietary guidance, product recommendations, education, and ongoing support. This approach is helping consumers better manage treatment-related lifestyle changes while creating opportunities for recurring engagement and product adoption.

In March 2025, The Vitamin Shoppe launched its GLP-1 Support supplement line under the Whole Health Rx platform. The portfolio includes protein, fiber, probiotic, multivitamin, and comprehensive nutritional-support formulations designed to help address nutrient gaps and digestive-health needs among individuals using GLP-1 medications.

U.S. GLP-1 Companion Products Market Trends

The U.S. GLP-1 companion product industry accounted for the largest share, at 85.9%, in 2025, due to its large GLP-1 user base, advanced digital health ecosystem, and growing consumer demand for personalized obesity management support. One of the most significant trends in the country is the increasing convergence of telehealth, digital coaching, and medication management into integrated consumer-facing platforms. Consumers are no longer seeking access to medication alone but increasingly demand continuous support, including meal planning, side-effect management, fitness guidance, and long-term habit formation. This trend is further supported by growing efforts to expand access to obesity treatment.

For instance, in 2026, the Centers for Medicare & Medicaid Services (CMS) launched the Medicare GLP-1 Bridge demonstration program to improve access to GLP-1 therapies for eligible beneficiaries, a move expected to increase the addressable consumer base for companion solutions. Additionally, Walmart expanded its digital health offerings in 2026 to include weight-management and GLP-1 support services through its virtual care ecosystem, reflecting the growing emphasis on comprehensive patient support.

Europe GLP-1 Companion Products Market Trends

The GLP-1 companion product industry in Europe accounted for a share of 22.1% in 2025, driven by the increasing emphasis on clinical nutrition and structured lifestyle support as part of long-term weight management programs. Consumers and healthcare professionals across the region are placing greater focus on ensuring adequate nutrient intake, maintaining physical function, and supporting healthy aging during GLP-1 treatment. This is encouraging demand for companion products that provide protein enrichment, micronutrient support, digestive wellness benefits, and portion-controlled nutrition.

In January 2026, Marks & Spencer launched a dedicated range of nutrient-dense food products designed for consumers using GLP-1 weight-loss medications. The portfolio includes high-protein meals, yogurt bowls, wraps, and snacks formulated to help individuals maintain adequate nutrient intake despite reduced appetite. The launch reflects the growing involvement of mainstream food retailers in meeting the evolving dietary requirements of GLP-1 users.

The Germany GLP-1 companion products market commands a significant share of Europe due to its strong healthcare infrastructure, increasing obesity prevalence, and high adoption of digital health solutions. Consumers typically exercise heightened scrutiny of health-related products and often prioritize evidence-based formulations over trend-driven wellness products. As a result, companion products that provide clear nutritional functionality, ingredient transparency, and clinically supported benefits are gaining traction among GLP-1 users. Germany’s aging population is contributing to demand for companion products that support healthy body composition, physical function, and nutritional adequacy during weight-management interventions. The market is further supported by rising consumer willingness to spend on premium health products that offer convenience, quality assurance, and measurable health outcomes.

Asia Pacific GLP-1 Companion Products Market Trends

The GLP-1 companion product industry in Asia Pacific is projected to grow at a CAGR of 12.7% from 2026 to 2033, driven by the increasing consumer focus on metabolic wellness, preventive nutrition, and personalized health management. Consumers across the region are becoming more proactive in managing their nutritional intake during GLP-1 therapy, driving demand for protein-enriched foods, hydration products, digestive health solutions, and nutrient-dense meal alternatives.

In March 2026, Japanese health-tech company MedIshin launched “Mend,” a nationwide medical weight-management platform that combines GLP-1 prescriptions, registered dietitian support, blood testing, and personalized health monitoring. The launch highlights the growing demand in Asia Pacific for integrated care models that combine medication with nutrition and lifestyle support, creating favorable conditions for GLP-1 companion products and personalized nutrition solutions.

The China GLP-1 companion products market is the fastest-growing in Asia Pacific, driven by a rapidly expanding obesity population, growing awareness of weight-related health risks, and strong domestic innovation in the metabolic health sector. One of the most important trends in the country is the emergence of locally developed obesity therapies and integrated weight-management ecosystems designed specifically for consumers. As the number of consumers receiving GLP-1 therapies increases, there is a growing demand for products that help optimize nutritional intake despite reduced appetite and lower food consumption. The approval of Innovent’s mazdutide in 2025, the world’s first GLP-1/glucagon dual agonist approved for chronic weight management, has significantly increased interest among consumers and healthcare providers in obesity treatment and related support services. Additionally, companies are increasingly leveraging digital platforms and e-commerce channels to distribute weight-management products and engage consumers throughout their treatment journey. China has also witnessed continued investment in next-generation obesity therapies, including the advancement of Novo Nordisk and United Biotechnology’s UBT251 program, highlighting the country’s growing importance in the global metabolic health landscape.

Central & South America GLP-1 Companion Products Market Trends

The GLP-1 companion product industry in Central & South America is projected to grow at 11.6% CAGR from 2026 to 2033, as consumers increasingly seek affordable nutritional support solutions that complement long-term weight management and metabolic health. One of the primary factors driving market growth is the gradual expansion of access to GLP-1 therapies across major countries such as Brazil, which is increasing awareness of the nutritional requirements associated with these treatments. Trend across the region is the rising use of private obesity clinics, endocrinology centers, and wellness programs that combine pharmacological treatment with nutritional counseling and lifestyle interventions. This is creating demand for companion products that help consumers maintain nutritional adequacy, support digestive health, and manage dietary changes associated with reduced appetite. As more consumers adopt GLP-1 medications, demand is rising for protein-rich foods, hydration products, digestive-health solutions, and nutrient-dense meal options that help address reduced appetite and support overall nutritional balance.

Middle East & Africa GLP-1 Companion Products Market Trends

The Middle East & Africa GLP-1 companion product industry is projected to grow at a CAGR of 12.2% from 2026 to 2033, driven by arising emphasis on preventive healthcare and chronic disease management, particularly among populations actively seeking solutions to improve metabolic health and overall well-being. The increasing focus on structured patient-support programs, with healthcare stakeholders emphasizing the importance of combining medication with nutrition planning, physical activity, and behavioral guidance. This creates favorable conditions for companion products designed to support treatment adherence, nutritional adequacy, and long-term lifestyle management. In addition, expanding pharmaceutical investment and improving the availability of GLP-1 therapies across several Middle Eastern and African markets are increasing awareness of the complementary role of nutrition and wellness products throughout the treatment journey. As consumers become more engaged in proactive health management, demand for specialized companion products is expected to strengthen across the region.

Eurasia GLP-1 Companion Product Market Trends

The GLP-1 companion product industry in Eurasia is projected to grow at a CAGR of 11.2% from 2026 to 2033 as the region experiences a rapid expansion in access to GLP-1 therapies, particularly through domestic manufacturing, local pharmaceutical innovation, and increasing availability of lower-cost alternatives. A major factor driving demand for companion products is the growing need for nutritional optimization and treatment-support solutions among first-time GLP-1 users, many of whom are seeking guidance on protein intake, hydration, digestive wellness, and sustainable dietary habits during treatment. The emergence of oral GLP-1 formulations and broader treatment accessibility is encouraging consumers to seek convenient, everyday nutritional solutions that can be integrated into long-term health-management routines. As awareness of treatment-support requirements increases, demand for protein-enriched foods, meal-support products, hydration solutions, and digestive-health formulations is expected to strengthen across Eurasian markets.

In November 2025, Promomed received regulatory approval for Semaltara, Russia’s first domestically produced oral semaglutide product. The launch expanded access to GLP-1 therapy through a non-injectable format and reflects the region’s growing focus on improving treatment accessibility. Increased adoption of oral therapies is expected to support demand for convenient companion nutrition products that can be integrated into daily routines.

Key GLP-1 Companion Products Company Insights

The GLP-1 companion products market is characterized by the growing presence of nutrition, wellness, functional food, dietary supplement, and digital health solution providers focused on supporting individuals throughout their GLP-1 treatment journey. Market participants are increasingly developing specialized product portfolios that address evolving consumer needs for nutritional adequacy, hydration, digestive wellness, metabolic health, and long-term weight management. Continuous innovation in high-protein foods, nutrient-dense meal solutions, functional beverages, vitamins, probiotics, and personalized wellness offerings is contributing to category expansion and product differentiation. In addition, companies are strengthening their market presence through omnichannel distribution strategies, including e-commerce platforms, direct-to-consumer channels, pharmacies, health and wellness retailers, and subscription-based service models, enabling broader consumer access to companion solutions.

Key GLP-1 Companion Products Companies

The following key companies have been profiled for this study of the GLP-1 companion products market.

• Nature Made
• Nestle S.A.
• Herba Life Ltd.
• The Vitamin Shoppe
• Conagra Brands Inc.
• Danone S.A.
• Abbott
• Amway Corp
• GNC
• Smoothie King

Recent Developments

• In January 2026, Maeva launched a science-backed nutrition system for GLP-1 users featuring targeted metabolic boosters, personalized nutrition shakes, and wellness products designed to support metabolic health during weight-loss treatment.
• In January 2026, Bodie*z expanded into the UK market with protein hydration powders targeting GLP-1 users, combining high-protein content with hydration benefits to support muscle preservation and recovery.
• In August 2025, Eden partnered with Gainful to introduce personalized hydration bundles and nutritional support programs tailored to individuals undergoing GLP-1 treatment, reflecting the increasing integration of hydration products within broader companion ecosystems.
• In May 2025, Oikos expanded beyond yogurt and introduced protein shakes specifically developed for users of GLP-1 medications, addressing increasing demand for protein-rich metabolic support products.

Global GLP-1 Companion Products Market Report Segmentation

This report forecasts revenue growth at the global, regional & country level and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global GLP-1 companion product market report based on product, distribution channel, and region:

• Product Outlook (Revenue, USD Billion, 2021 – 2033)
  • Muscle Preservation Powders
    • Protein Powders
    •  RTD Protein Beverages
    •  Protein Bars
    •  Others
  • Digestive Health Products
    • Fiber Supplements
    • Probiotics Supplements
    • Digestive Enzyme Supplements
    • Others
  • Nutrient Density Support
    • Multivitamin Supplements
    • Meal Replacement Products
    • Others
  • Appetite & Metabolic Support
    • Satiety Support Products
    • Appetite Management Supplements
    • Others
  • Hydration & Recovery Products
    • Electrolyte Beverages
    • Recovery Hydration Products
    • Functional Hydration Mixes
    • Others
  • Others
• Distribution Channel Outlook (Revenue, USD Billion, 2021 – 2033)
  • Hypermarkets & Supermarkets
  • Pharmacies & Drug Stores
  • Specialty Stores
  • D2C
  • Online (E-commerce)
  • MLM (Direct Sales)
  • Others
• Regional Outlook (Revenue, USD Billion, 2021 – 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia & New Zealand
    • South Korea
    • Indonesia
    • Malaysia
    • Vietnam
    • Taiwan
  • Central & South America
    • Brazil
    • Colombia
    • Ecuador
    • El Salvador
    • Peru
    • Honduras
  • Middle East & Africa
    • Saudi Arabia
    • Turkey
  • Eurasia
    • Mongolia
    • Kazakhstan
    • Uzbekistan

Research Methodology

The GLP-1 companion product market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing-reconciling supply-side and demand-side estimates-and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each GLP-1 companion product segment quantified using the revenue-capture definitions in the table below.

Delivered Customizations

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Market Definition
1.3. Information Procurement
1.3.1. Purchased Database
1.3.2. GVR’s Internal Database
1.3.3. Secondary Sources & Third-Party Perspectives
1.3.4. Primary Research
1.4. Information Analysis
1.4.1. Data Analysis Models
1.5. Market Formulation & Data Visualization
1.6. Data Validation & Publishing
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Product Outlook
2.3. Distribution Channel Outlook
2.4. Competitive Landscape Outlook
Chapter 3. GLP-1 Companion Product Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. GLP-1 Companion Product Market Size & Growth Rate Overview, 2021 – 2033 (USD Billion)
3.2. Penetration & Growth Prospect Mapping
3.3. Industry Value Chain Analysis
3.3.1. Raw Material Trends Outlooks
3.3.2. Manufacturing and Technology Trends
3.3.3. Profit Margin Analysis
3.4. Market Dynamics
3.4.1. Market Driver Analysis
3.4.2. Market Restraint Analysis
3.4.3. Market Opportunities
3.4.4. Market Challenges
3.5. Industry Analysis – Porter’s Five Forces Analysis
3.6. Market Entry Strategies
Chapter 4. GLP-1 Companion Product Market: Consumer Behavior Analysis
4.1. Demographic Analysis
4.2. Consumer Trends & Preferences
4.3. Factors Influencing Buying Behavior
4.4. Consumer Service Adoption Trends
4.5. Key Observations & Findings
Chapter 5. GLP-1 Companion Product Market: Product Estimates & Trend Analysis
5.1. GLP-1 Companion Product Market, by Product: Key Takeaways
5.2. Product Movement Analysis & Market Share, 2025 & 2033
5.3. Market Estimates & Forecasts, by Product, 2021 – 2033 (USD Billion)
5.3.1. Muscle Preservation Powders
5.3.1.1. Market estimates and forecast, 2021 – 2033 (USD Billion)
5.3.1.2. Protein Powders
5.3.1.2.1. Market estimates and forecast, 2021 – 2033 (USD Billion)
5.3.1.3. RTD Protein Beverages
5.3.1.3.1. Market estimates and forecast, 2021 – 2033 (USD Billion)
5.3.1.4. Protein Bars
5.3.1.4.1. Market estimates and forecast, 2021 – 2033 (USD Billion)
5.3.1.5. Others
5.3.1.5.1. Market estimates and forecast, 2021 – 2033 (USD Billion)
5.3.2. Digestive Health Products
5.3.2.1. Market estimates and forecast, 2021 – 2033 (USD Billion)
5.3.2.2. Fiber Supplements
5.3.2.2.1. Market estimates and forecast, 2021 – 2033 (USD Billion)
5.3.2.3. Probiotics Supplements
5.3.2.3.1. Market estimates and forecast, 2021 – 2033 (USD Billion)
5.3.2.4. Digestive Enzyme Supplements
5.3.2.4.1. Market estimates and forecast, 2021 – 2033 (USD Billion)
5.3.2.5. Others
5.3.2.5.1. Market estimates and forecast, 2021 – 2033 (USD Billion)
5.3.3. Nutrient Density Support
5.3.3.1. Market estimates and forecast, 2021 – 2033 (USD Billion)
5.3.3.2. Multivitamin Supplements
5.3.3.2.1. Market estimates and forecast, 2021 – 2033 (USD Billion)
5.3.3.3. Meal Replacement Products
5.3.3.3.1. Market estimates and forecast, 2021 – 2033 (USD Billion)
5.3.3.4. Others
5.3.3.4.1. Market estimates and forecast, 2021 – 2033 (USD Billion)
5.3.4. Appetite & Metabolic Support
5.3.4.1. Market estimates and forecast, 2021 – 2033 (USD Billion)
5.3.4.2. Satiety Support Products
5.3.4.2.1. Market estimates and forecast, 2021 – 2033 (USD Billion)
5.3.4.3. Appetite Management Supplements
5.3.4.3.1. Market estimates and forecast, 2021 – 2033 (USD Billion)
5.3.4.4. Others
5.3.4.4.1. Market estimates and forecast, 2021 – 2033 (USD Billion)
5.3.5. Hydration & Recovery Products
5.3.5.1. Market estimates and forecast, 2021 – 2033 (USD Billion)
5.3.5.2. Electrolyte Beverages
5.3.5.2.1. Market estimates and forecast, 2021 – 2033 (USD Billion)
5.3.5.3. Recovery Hydration Products
5.3.5.3.1. Market estimates and forecast, 2021 – 2033 (USD Billion)
5.3.5.4. Functional Hydration Mixes
5.3.5.4.1. Market estimates and forecast, 2021 – 2033 (USD Billion)
5.3.5.5. Others
5.3.5.5.1. Market estimates and forecast, 2021 – 2033 (USD Billion)
5.3.6. Others
5.3.6.1. Market estimates and forecast, 2021 – 2033 (USD Billion)
Chapter 6. GLP-1 Companion Product Market: Distribution Channel Estimates & Trend Analysis
6.1. GLP-1 Companion Product Market, by Distribution Channel: Key Takeaways
6.2. Distribution Channel Movement Analysis & Market Share, 2025 & 2033
6.3. Market Estimates & Forecasts, by Distribution Channel, 2021 – 2033 (USD Billion)
6.3.1. Hypermarkets & Supermarkets
6.3.1.1. Market estimates and forecast, 2021 – 2033 (USD Billion)
6.3.2. Pharmacies & Drug Stores
6.3.2.1. Market estimates and forecast, 2021 – 2033 (USD Billion)
6.3.3. Specialty Stores
6.3.3.1. Market estimates and forecast, 2021 – 2033 (USD Billion)
6.3.4. D2C
6.3.4.1. Market estimates and forecast, 2021 – 2033 (USD Billion)
6.3.5. Online (E-commerce)
6.3.5.1. Market estimates and forecast, 2021 – 2033 (USD Billion)
6.3.6. MLM (Direct Sales)
6.3.6.1. Market estimates and forecast, 2021 – 2033 (USD Billion)
6.3.7. Others
6.3.7.1. Market estimates and forecast, 2021 – 2033 (USD Billion)
Chapter 7. GLP-1 Companion Product Market: Regional Estimates & Trend Analysis
7.1. GLP-1 Companion Product Market: Regional Outlook
7.2. Regional Movement Analysis & Market Share, 2025 & 2033
7.3. Market Estimates & Forecasts, by Region & Country, 2021 – 2033 (USD Billion)
7.3.1. North America
7.3.1.1. Market estimates and forecast, 2021 – 2033 (USD Billion)
7.3.1.2. U.S.
7.3.1.2.1. Key country dynamics
7.3.1.2.2. Market estimates and forecast, 2021 – 2033 (USD Billion)
7.3.1.3. Canada
7.3.1.3.1. Key country dynamics
7.3.1.3.2. Market estimates and forecast, 2021 – 2033 (USD Billion)
7.3.1.4. Mexico
7.3.1.4.1. Key country dynamics
7.3.1.4.2. Market estimates and forecast, 2021 – 2033 (USD Billion)
7.3.2. Europe
7.3.2.1. Market estimates and forecast, 2021 – 2033 (USD Billion)
7.3.2.2. Germany
7.3.2.2.1. Key country dynamics
7.3.2.2.2. Market estimates and forecast, 2021 – 2033 (USD Billion)
7.3.2.3. UK
7.3.2.3.1. Key country dynamics
7.3.2.3.2. Market estimates and forecast, 2021 – 2033 (USD Billion)
7.3.2.4. France
7.3.2.4.1. Key country dynamics
7.3.2.4.2. Market estimates and forecast, 2021 – 2033 (USD Billion)
7.3.2.5. Italy
7.3.2.5.1. Key country dynamics
7.3.2.5.2. Market estimates and forecast, 2021 – 2033 (USD Billion)
7.3.3. Asia Pacific
7.3.3.1. Market estimates and forecast, 2021 – 2033 (USD Billion)
7.3.3.2. China
7.3.3.2.1. Key country dynamics
7.3.3.2.2. Market estimates and forecast, 2021 – 2033 (USD Billion)
7.3.3.3. Japan
7.3.3.3.1. Key country dynamics
7.3.3.3.2. Market estimates and forecast, 2021 – 2033 (USD Billion)
7.3.3.4. India
7.3.3.4.1. Key country dynamics
7.3.3.4.2. Market estimates and forecast, 2021 – 2033 (USD Billion)
7.3.3.5. Australia & New Zealand
7.3.3.5.1. Key country dynamics
7.3.3.5.2. Market estimates and forecast, 2021 – 2033 (USD Billion)
7.3.3.6. South Korea
7.3.3.6.1. Key country dynamics
7.3.3.6.2. Market estimates and forecast, 2021 – 2033 (USD Billion)
7.3.3.7. Indonesia
7.3.3.7.1. Key country dynamics
7.3.3.7.2. Market estimates and forecast, 2021 – 2033 (USD Billion)
7.3.3.8. Malaysia
7.3.3.8.1. Key country dynamics
7.3.3.8.2. Market estimates and forecast, 2021 – 2033 (USD Billion)
7.3.3.9. Vietnam
7.3.3.9.1. Key country dynamics
7.3.3.9.2. Market estimates and forecast, 2021 – 2033 (USD Billion)
7.3.3.10. Taiwan
7.3.3.10.1. Key country dynamics
7.3.3.10.2. Market estimates and forecast, 2021 – 2033 (USD Billion)
7.3.4. Central & South America
7.3.4.1. Market estimates and forecast, 2021 – 2033 (USD Billion)
7.3.4.2. Brazil
7.3.4.2.1. Key country dynamics
7.3.4.2.2. Market estimates and forecast, 2021 – 2033 (USD Billion)
7.3.4.3. Colombia
7.3.4.3.1. Key country dynamics
7.3.4.3.2. Market estimates and forecast, 2021 – 2033 (USD Billion)
7.3.4.4. Ecuador
7.3.4.4.1. Key country dynamics
7.3.4.4.2. Market estimates and forecast, 2021 – 2033 (USD Billion)
7.3.4.5. El Salvador
7.3.4.5.1. Key country dynamics
7.3.4.5.2. Market estimates and forecast, 2021 – 2033 (USD Billion)
7.3.4.6. Peru
7.3.4.6.1. Key country dynamics
7.3.4.6.2. Market estimates and forecast, 2021 – 2033 (USD Billion)
7.3.4.7. Honduras
7.3.4.7.1. Key country dynamics
7.3.4.7.2. Market estimates and forecast, 2021 – 2033 (USD Billion)
7.3.5. Middle East & Africa
7.3.5.1. Market estimates and forecast, 2021 – 2033 (USD Billion)
7.3.5.2. Saudi Arabia
7.3.5.2.1. Key country dynamics
7.3.5.2.2. Market estimates and forecast, 2021 – 2033 (USD Billion)
7.3.5.3. Turkey
7.3.5.3.1. Key country dynamics
7.3.5.3.2. Market estimates and forecast, 2021 – 2033 (USD Billion)
7.3.6. Eurasia
7.3.6.1. Market estimates and forecast, 2021 – 2033 (USD Billion)
7.3.6.2. Mongolia
7.3.6.2.1. Key country dynamics
7.3.6.2.2. Market estimates and forecast, 2021 – 2033 (USD Billion)
7.3.6.3. Kazakhstan
7.3.6.3.1. Key country dynamics
7.3.6.3.2. Market estimates and forecast, 2021 – 2033 (USD Billion)
7.3.6.4. Uzbekistan
7.3.6.4.1. Key country dynamics
7.3.6.4.2. Market estimates and forecast, 2021 – 2033 (USD Billion)
Chapter 8. Competitive Analysis
8.1. Recent Developments & Impact Analysis by Key Market Participants
8.2. Company Categorization
8.3. Participant’s Overview
8.4. Financial Performance
8.5. Product Portfolios
8.6. Company Market Share Analysis, 2025 (%)
8.7. Company Heat Map Analysis
8.8. Strategy Mapping
8.9. Company Profiles
8.9.1. Nature Made
8.9.1.1. Company Overview
8.9.1.2. Financial Performance
8.9.1.3. Product Portfolios
8.9.1.4. Strategic Initiatives
8.9.2. Nestle S.A.
8.9.2.1. Company Overview
8.9.2.2. Financial Performance
8.9.2.3. Product Portfolios
8.9.2.4. Strategic Initiatives
8.9.3. HerbaLife Ltd.
8.9.3.1. Company Overview
8.9.3.2. Financial Performance
8.9.3.3. Product Portfolios
8.9.3.4. Strategic Initiatives
8.9.4. The Vitamin Shoppe
8.9.4.1. Company Overview
8.9.4.2. Financial Performance
8.9.4.3. Product Portfolios
8.9.4.4. Strategic Initiatives
8.9.5. Conagra Brands Inc.
8.9.5.1. Company Overview
8.9.5.2. Financial Performance
8.9.5.3. Product Portfolios
8.9.5.4. Strategic Initiatives
8.9.6. Danone S.A.
8.9.6.1. Company Overview
8.9.6.2. Financial Performance
8.9.6.3. Type Portfolios
8.9.6.4. Strategic Initiatives
8.9.7. Abbott
8.9.7.1. Company Overview
8.9.7.2. Financial Performance
8.9.7.3. Product Portfolios
8.9.7.4. Strategic Initiatives
8.9.8. Amway Corp
8.9.8.1. Company Overview
8.9.8.2. Financial Performance
8.9.8.3. Product Portfolios
8.9.8.4. Strategic Initiatives
8.9.9. GNC
8.9.9.1. Company Overview
8.9.9.2. Financial Performance
8.9.9.3. Product Portfolios
8.9.9.4. Strategic Initiatives
8.9.10. Smoothie King
8.9.10.1. Company Overview
8.9.10.2. Financial Performance
8.9.10.3. Product Portfolios
8.9.10.4. Strategic Initiatives

List of Tables

Table 1 GLP-1 companion product market – Key market driver analysis
Table 2 GLP-1 companion product market – Key market restraint analysis
Table 3 GLP-1 companion product market estimates and forecast, by product (USD Billion)
Table 4 GLP-1 companion product market estimates and forecast, by distribution channel (USD Billion)
Table 5 North America GLP-1 companion product market estimates and forecast, 2021 – 2033 (USD Billion)
Table 6 North America GLP-1 companion product market revenue estimates and forecast, by product, 2021 – 2033 (USD Billion)
Table 7 North America GLP-1 companion product market revenue estimates and forecast, by distribution channel, 2021 – 2033 (USD Billion)
Table 8 U.S. macro-economic outlay
Table 9 U.S. GLP-1 companion product market estimates and forecast, 2021 – 2033 (USD Billion)
Table 10 U.S. GLP-1 companion product market revenue estimates and forecast, by product, 2021 – 2033 (USD Billion)
Table 11 U.S. GLP-1 companion product market revenue estimates and forecast, by distribution channel, 2021 – 2033 (USD Billion)
Table 12 Canada macro-economic outlay
Table 13 Canada GLP-1 companion product market estimates and forecast, 2021 – 2033 (USD Billion)
Table 14 Canada GLP-1 companion product market revenue estimates and forecast, by product, 2021 – 2033 (USD Billion)
Table 15 Canada GLP-1 companion product market revenue estimates and forecast, by distribution channel, 2021 – 2033 (USD Billion)
Table 16 Mexico macro-economic outlay
Table 17 Mexico GLP-1 companion product market estimates and forecast, 2021 – 2033 (USD Billion)
Table 18 Mexico GLP-1 companion product market revenue estimates and forecast, by product, 2021 – 2033 (USD Billion)
Table 19 Mexico GLP-1 companion product market revenue estimates and forecast, by distribution channel, 2021 – 2033 (USD Billion)
Table 20 Europe GLP-1 companion product market estimates and forecast, 2021 – 2033 (USD Billion)
Table 21 Europe GLP-1 companion product market revenue estimates and forecast, by product, 2021 – 2033 (USD Billion)
Table 22 Europe GLP-1 companion product market revenue estimates and forecast, by distribution channel, 2021 – 2033 (USD Billion)
Table 23 Germany macro-economic outlay
Table 24 Germany GLP-1 companion product market estimates and forecast, 2021 – 2033 (USD Billion)
Table 25 Germany GLP-1 companion product market revenue estimates and forecast, by product, 2021 – 2033 (USD Billion)
Table 26 Germany GLP-1 companion product market revenue estimates and forecast, by distribution channel, 2021 – 2033 (USD Billion)
Table 27 UK macro-economic outlay
Table 28 UK GLP-1 companion product market estimates and forecast, 2021 – 2033 (USD Billion)
Table 29 UK GLP-1 companion product market revenue estimates and forecast, by product, 2021 – 2033 (USD Billion)
Table 30 UK GLP-1 companion product market revenue estimates and forecast, by distribution channel, 2021 – 2033 (USD Billion)
Table 31 France macro-economic outlay
Table 32 France GLP-1 companion product market estimates and forecast, 2021 – 2033 (USD Billion)
Table 33 France GLP-1 companion product market revenue estimates and forecast, by product, 2021 – 2033 (USD Billion)
Table 34 France GLP-1 companion product market revenue estimates and forecast, by distribution channel, 2021 – 2033 (USD Billion)
Table 35 Italy macro-economic outlay
Table 36 Italy GLP-1 companion product market estimates and forecast, 2021 – 2033 (USD Billion)
Table 37 Italy GLP-1 companion product market revenue estimates and forecast, by product, 2021 – 2033 (USD Billion)
Table 38 Italy GLP-1 companion product market revenue estimates and forecast, by distribution channel, 2021 – 2033 (USD Billion)
Table 39 Asia Pacific GLP-1 companion product market estimates and forecast, 2021 – 2033 (USD Billion)
Table 40 Asia Pacific GLP-1 companion product market revenue estimates and forecast, by product, 2021 – 2033 (USD Billion)
Table 41 Asia Pacific GLP-1 companion product market revenue estimates and forecast, by distribution channel, 2021 – 2033 (USD Billion)
Table 42 China macro-economic outlay
Table 43 China GLP-1 companion product market estimates and forecast, 2021 – 2033 (USD Billion)
Table 44 China GLP-1 companion product market revenue estimates and forecast, by product, 2021 – 2033 (USD Billion)
Table 45 China GLP-1 companion product market revenue estimates and forecast, by distribution channel, 2021 – 2033 (USD Billion)
Table 46 Japan macro-economic outlay
Table 47 Japan GLP-1 companion product market estimates and forecast, 2021 – 2033 (USD Billion)
Table 48 Japan GLP-1 companion product market revenue estimates and forecast, by product, 2021 – 2033 (USD Billion)
Table 49 Japan GLP-1 companion product market revenue estimates and forecast, by distribution channel, 2021 – 2033 (USD Billion)
Table 50 India macro-economic outlay
Table 51 India GLP-1 companion product market estimates and forecast, 2021 – 2033 (USD Billion)
Table 52 India GLP-1 companion product market revenue estimates and forecast, by product, 2021 – 2033 (USD Billion)
Table 53 India GLP-1 companion product market revenue estimates and forecast, by distribution channel, 2021 – 2033 (USD Billion)
Table 54 Australia & New Zealand macro-economic outlay
Table 55 Australia & New Zealand GLP-1 companion product market estimates and forecast, 2021 – 2033 (USD Billion)
Table 56 Australia & New Zealand GLP-1 companion product market revenue estimates and forecast, by product, 2021 – 2033 (USD Billion)
Table 57 Australia & New Zealand GLP-1 companion product market revenue estimates and forecast, by distribution channel, 2021 – 2033 (USD Billion)
Table 58 South Korea macro-economic outlay
Table 59 South Korea GLP-1 companion product market estimates and forecast, 2021 – 2033 (USD Billion)
Table 60 South Korea GLP-1 companion product market revenue estimates and forecast, by product, 2021 – 2033 (USD Billion)
Table 61 South Korea GLP-1 companion product market revenue estimates and forecast, by distribution channel, 2021 – 2033 (USD Billion)
Table 62 Indonesia macro-economic outlay
Table 63 Indonesia GLP-1 companion product market estimates and forecast, 2021 – 2033 (USD Billion)
Table 64 Indonesia GLP-1 companion product market revenue estimates and forecast, by product, 2021 – 2033 (USD Billion)
Table 65 Indonesia GLP-1 companion product market revenue estimates and forecast, by distribution channel, 2021 – 2033 (USD Billion)
Table 66 Malaysia macro-economic outlay
Table 67 Malaysia GLP-1 companion product market estimates and forecast, 2021 – 2033 (USD Billion)
Table 68 Malaysia GLP-1 companion product market revenue estimates and forecast, by product, 2021 – 2033 (USD Billion)
Table 69 Malaysia GLP-1 companion product market revenue estimates and forecast, by distribution channel, 2021 – 2033 (USD Billion)
Table 70 Vietnam macro-economic outlay
Table 71 Vietnam GLP-1 companion product market estimates and forecast, 2021 – 2033 (USD Billion)
Table 72 Vietnam GLP-1 companion product market revenue estimates and forecast, by product, 2021 – 2033 (USD Billion)
Table 73 Vietnam GLP-1 companion product market revenue estimates and forecast, by distribution channel, 2021 – 2033 (USD Billion)
Table 74 Taiwan macro-economic outlay
Table 75 Taiwan GLP-1 companion product market estimates and forecast, 2021 – 2033 (USD Billion)
Table 76 Taiwan GLP-1 companion product market revenue estimates and forecast, by product, 2021 – 2033 (USD Billion)
Table 77 Taiwan GLP-1 companion product market revenue estimates and forecast, by distribution channel, 2021 – 2033 (USD Billion)
Table 78 Central & South America GLP-1 companion product market estimates and forecast, 2021 – 2033 (USD Billion)
Table 79 Central & South America GLP-1 companion product market revenue estimates and forecast by product, 2021 – 2033 (USD Billion)
Table 80 Central & South America GLP-1 companion product market revenue estimates and forecast by distribution channel, 2021 – 2033 (USD Billion)
Table 81 Brazil macro-economic outlay
Table 82 Brazil GLP-1 companion product market estimates and forecast, 2021 – 2033 (USD Billion)
Table 83 Brazil GLP-1 companion product market revenue estimates and forecast by product, 2021 – 2033 (USD Billion)
Table 84 Brazil GLP-1 companion product market revenue estimates and forecast by distribution channel, 2021 – 2033 (USD Billion)
Table 85 Colombia macro-economic outlay
Table 86 Colombia GLP-1 companion product market estimates and forecast, 2021 – 2033 (USD Billion)
Table 87 Colombia GLP-1 companion product market revenue estimates and forecast, by product, 2021 – 2033 (USD Billion)
Table 88 Colombia GLP-1 companion product market revenue estimates and forecast, by distribution channel, 2021 – 2033 (USD Billion)
Table 89 Ecuador macro-economic outlay
Table 90 Ecuador GLP-1 companion product market estimates and forecast, 2021 – 2033 (USD Billion)
Table 91 Ecuador GLP-1 companion product market revenue estimates and forecast by product, 2021 – 2033 (USD Billion)
Table 92 Ecuador GLP-1 companion product market revenue estimates and forecast by distribution channel, 2021 – 2033 (USD Billion)
Table 93 El Salvador macro-economic outlay
Table 94 El Salvador GLP-1 companion product market estimates and forecast, 2021 – 2033 (USD Billion)
Table 95 El Salvador GLP-1 companion product market revenue estimates and forecast by product, 2021 – 2033 (USD Billion)
Table 96 El Salvador GLP-1 companion product market revenue estimates and forecast by distribution channel, 2021 – 2033 (USD Billion)
Table 97 Peru macro-economic outlay
Table 98 Peru GLP-1 companion product market estimates and forecast, 2021 – 2033 (USD Billion)
Table 99 Peru GLP-1 companion product market revenue estimates and forecast by product, 2021 – 2033 (USD Billion)
Table 100 Peru GLP-1 companion product market revenue estimates and forecast by distribution channel, 2021 – 2033 (USD Billion)
Table 101 Honduras macro-economic outlay
Table 102 Honduras GLP-1 companion product market estimates and forecast, 2021 – 2033 (USD Billion)
Table 103 Honduras GLP-1 companion product market revenue estimates and forecast by product, 2021 – 2033 (USD Billion)
Table 104 Honduras GLP-1 companion product market revenue estimates and forecast by distribution channel, 2021 – 2033 (USD Billion)
Table 105 Middle East & Africa GLP-1 companion product market estimates and forecast, 2021 – 2033 (USD Billion)
Table 106 Middle East & Africa GLP-1 companion product market revenue estimates and forecast by product, 2021 – 2033 (USD Billion)
Table 107 Middle East & Africa GLP-1 companion product market revenue estimates and forecast by distribution channel, 2021 – 2033 (USD Billion)
Table 108 Saudi Arabia macro-economic outlay
Table 109 Saudi Arabia GLP-1 companion product market estimates and forecast, 2021 – 2033 (USD Billion)
Table 110 Saudi Arabia GLP-1 companion product market revenue estimates and forecast by product, 2021 – 2033 (USD Billion)
Table 111 Saudi Arabia GLP-1 companion product market revenue estimates and forecast by distribution channel, 2021 – 2033 (USD Billion)
Table 112 Turkey macro-economic outlay
Table 113 Turkey GLP-1 companion product market estimates and forecast, 2021 – 2033 (USD Billion)
Table 114 Turkey GLP-1 companion product market revenue estimates and forecast by product, 2021 – 2033 (USD Billion)
Table 115 Turkey GLP-1 companion product market revenue estimates and forecast by distribution channel, 2021 – 2033 (USD Billion)
Table 116 Eurasia GLP-1 companion product market estimates and forecast, 2021 – 2033 (USD Billion)
Table 117 Eurasia GLP-1 companion product market revenue estimates and forecast by product, 2021 – 2033 (USD Billion)
Table 118 Eurasia GLP-1 companion product market revenue estimates and forecast by distribution channel, 2021 – 2033 (USD Billion)
Table 119 Mongolia macro-economic outlay
Table 120 Mongolia GLP-1 companion product market estimates and forecast, 2021 – 2033 (USD Billion)
Table 121 Mongolia GLP-1 companion product market revenue estimates and forecast by product, 2021 – 2033 (USD Billion)
Table 122 Mongolia GLP-1 companion product market revenue estimates and forecast by distribution channel, 2021 – 2033 (USD Billion)
Table 123 Kazakhstan macro-economic outlay
Table 124 Kazakhstan GLP-1 companion product market estimates and forecast, 2021 – 2033 (USD Billion)
Table 125 Kazakhstan GLP-1 companion product market revenue estimates and forecast by product, 2021 – 2033 (USD Billion)
Table 126 Kazakhstan GLP-1 companion product market revenue estimates and forecast by distribution channel, 2021 – 2033 (USD Billion)
Table 127 Uzbekistan macro-economic outlay
Table 128 Uzbekistan GLP-1 companion product market estimates and forecast, 2021 – 2033 (USD Billion)
Table 129 Uzbekistan GLP-1 companion product market revenue estimates and forecast by product, 2021 – 2033 (USD Billion)
Table 130 Uzbekistan GLP-1 companion product market revenue estimates and forecast by distribution channel, 2021 – 2033 (USD Billion)
Table 131 Recent developments & impact analysis by key market participants
Table 132 Company market share, 2025
Table 133 Company heat map analysis
Table 134 Companies undergoing key strategies

List of Figures

Fig. 1 GLP-1 companion product market segmentation
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Primary research approaches
Fig. 5 Primary research process
Fig. 6 Market snapshot
Fig. 7 Product snapshot
Fig. 8 Distribution channel snapshot
Fig. 9 Regional snapshot
Fig. 10 Competitive landscape snapshot
Fig. 11 GLP-1 companion product market size, 2021 to 2033 (USD Billion)
Fig. 12 GLP-1 companion product market: Penetration & growth prospect mapping
Fig. 13 GLP-1 companion product market: Value chain analysis
Fig. 14 GLP-1 companion product market: Profit margin analysis
Fig. 15 GLP-1 companion product market: Market dynamics
Fig. 16 GLP-1 companion product market: Porter’s five forces analysis
Fig. 17 Factors influencing buying decisions for GLP-1 companion product
Fig. 18 GLP-1 companion product market, by product: Key Takeaways
Fig. 19 GLP-1 companion product market: Product movement analysis, 2025 & 2033 (%)
Fig. 20 Muscle preservation powders market estimates and forecast, 2021 – 2033 (USD Billion)
Fig. 21 Protein powders market estimates and forecast, 2021 – 2033 (USD Billion)
Fig. 22 RTD protein beverages market estimates and forecast, 2021 – 2033 (USD Billion)
Fig. 23 Protein bars market estimates and forecast, 2021 – 2033 (USD Billion)
Fig. 24 Others market estimates and forecast, 2021 – 2033 (USD Billion)
Fig. 25 Digestive health products market estimates and forecast, 2021 – 2033 (USD Billion)
Fig. 26 Fiber supplements market estimates and forecast, 2021 – 2033 (USD Billion)
Fig. 27 Probiotics supplements market estimates and forecast, 2021 – 2033 (USD Billion)
Fig. 28 Digestive enzyme supplements market estimates and forecast, 2021 – 2033 (USD Billion)
Fig. 29 Others market estimates and forecast, 2021 – 2033 (USD Billion)
Fig. 30 Nutrient density support products market estimates and forecast, 2021 – 2033 (USD Billion)
Fig. 31 Multivitamin supplements market estimates and forecast, 2021 – 2033 (USD Billion)
Fig. 32 Meal replacement products market estimates and forecast, 2021 – 2033 (USD Billion)
Fig. 33 Others market estimates and forecast, 2021 – 2033 (USD Billion)
Fig. 34 Appetite & metabolic support products market estimates and forecast, 2021 – 2033 (USD Billion)
Fig. 35 Satiety support products market estimates and forecast, 2021 – 2033 (USD Billion)
Fig. 36 Appetite management supplements market estimates and forecast, 2021 – 2033 (USD Billion)
Fig. 37 Others market estimates and forecast, 2021 – 2033 (USD Billion)
Fig. 38 Hydration & recovery products market estimates and forecast, 2021 – 2033 (USD Billion)
Fig. 39 Electrolyte beverages market estimates and forecast, 2021 – 2033 (USD Billion)
Fig. 40 Recovery hydration products market estimates and forecast, 2021 – 2033 (USD Billion)
Fig. 41 Functional hydration mixes market estimates and forecast, 2021 – 2033 (USD Billion)
Fig. 42 Others market estimates and forecast, 2021 – 2033 (USD Billion)
Fig. 43 Others market estimates and forecast, 2021 – 2033 (USD Billion)
Fig. 44 GLP-1 companion product market: Distribution channel movement analysis, 2025 & 2033 (%)
Fig. 45 GLP-1 companion product market estimates and forecasts through hypermarkets & supermarkets, 2021 – 2033 (USD Billion)
Fig. 46 GLP-1 companion product market estimates and forecasts through pharmacies & drug stores, 2021 – 2033 (USD Billion)
Fig. 47 GLP-1 companion product market estimates and forecasts through specialty stores, 2021 – 2033 (USD Billion)
Fig. 48 GLP-1 companion product market estimates and forecasts through D2C, 2021 – 2033 (USD Billion)
Fig. 49 GLP-1 companion product market estimates and forecasts through online (e-commerce), 2021 – 2033 (USD Billion)
Fig. 50 GLP-1 companion product market estimates and forecasts through MLM (direct sales), 2021 – 2033 (USD Billion)
Fig. 51 GLP-1 companion product market estimates and forecasts through others, 2021 – 2033 (USD Billion)
Fig. 52 GLP-1 companion product market: Regional outlook, 2025 & 2033 (USD Billion)
Fig. 53 Regional marketplace: Key takeaways
Fig. 54 North America GLP-1 companion product market estimates and forecast, 2021 – 2033 (USD Billion)
Fig. 55 U.S. GLP-1 companion product market estimates and forecast, 2021 – 2033 (USD Billion)
Fig. 56 Canada GLP-1 companion product market estimates and forecast, 2021 – 2033 (USD Billion)
Fig. 57 Mexico GLP-1 companion product market estimates and forecast, 2021 – 2033 (USD Billion)
Fig. 58 Europe GLP-1 companion product market estimates and forecast, 2021 – 2033 (USD Billion)
Fig. 59 UK GLP-1 companion product market estimates and forecast, 2021 – 2033 (USD Billion)
Fig. 60 Germany GLP-1 companion product market estimates and forecast, 2021 – 2033 (USD Billion)
Fig. 61 France GLP-1 companion product market estimates and forecast, 2021 – 2033 (USD Billion)
Fig. 62 Italy GLP-1 companion product market estimates and forecast, 2021 – 2033 (USD Billion)
Fig. 63 Asia Pacific GLP-1 companion product market estimates and forecast, 2021 – 2033 (USD Billion)
Fig. 64 China GLP-1 companion product market estimates and forecast, 2021 – 2033 (USD Billion)
Fig. 65 Japan GLP-1 companion product market estimates and forecast, 2021 – 2033 (USD Billion)
Fig. 66 India GLP-1 companion product market estimates and forecast, 2021 – 2033 (USD Billion)
Fig. 67 Australia & New Zealand GLP-1 companion product market estimates and forecast, 2021 – 2033 (USD Billion)
Fig. 68 South Korea GLP-1 companion product market estimates and forecast, 2021 – 2033 (USD Billion)
Fig. 69 Indonesia GLP-1 companion product market estimates and forecast, 2021 – 2033 (USD Billion)
Fig. 70 Malaysia GLP-1 companion product market estimates and forecast, 2021 – 2033 (USD Billion)
Fig. 71 Vietnam GLP-1 companion product market estimates and forecast, 2021 – 2033 (USD Billion)
Fig. 72 Taiwan GLP-1 companion product market estimates and forecast, 2021 – 2033 (USD Billion)
Fig. 73 Central & South America GLP-1 companion product market estimates and forecast, 2021 – 2033 (USD Billion)
Fig. 74 Brazil GLP-1 companion product market estimates and forecast, 2021 – 2033 (USD Billion)
Fig. 75 Colombia GLP-1 companion product market estimates and forecast, 2021 – 2033 (USD Billion)
Fig. 76 Ecuador GLP-1 companion product market estimates and forecast, 2021 – 2033 (USD Billion)
Fig. 77 El Salvador GLP-1 companion product market estimates and forecast, 2021 – 2033 (USD Billion)
Fig. 78 Peru GLP-1 companion product market estimates and forecast, 2021 – 2033 (USD Billion)
Fig. 79 Honduras GLP-1 companion product market estimates and forecast, 2021 – 2033 (USD Billion)
Fig. 80 Middle East & Africa GLP-1 companion product market estimates and forecast, 2021 – 2033 (USD Billion)
Fig. 81 Saudi Arabia GLP-1 companion product market estimates and forecast, 2021 – 2033 (USD Billion)
Fig. 82 Turkey GLP-1 companion product market estimates and forecast, 2021 – 2033 (USD Billion)
Fig. 83 Eurasia GLP-1 companion product market estimates and forecast, 2021 – 2033 (USD Billion)
Fig. 84 Mongolia GLP-1 companion product market estimates and forecast, 2021 – 2033 (USD Billion)
Fig. 85 Kazakhstan GLP-1 companion product market estimates and forecast, 2021 – 2033 (USD Billion)
Fig. 86 Uzbekistan GLP-1 companion product market estimates and forecast, 2021 – 2033 (USD Billion)
Fig. 87 Key company categorization
Fig. 88 Company market share analysis, 2025
Fig. 89 Strategic framework of the GLP-1 companion product market

---

---